Terrie Curran
President and Chief Executive at Phathom Pharmaceuticals Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Phathom Pharmaceuticals Inc., 3 years.
Chief executive roles
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 27, 2026 | Arcutis Biotherapeutics Inc. | Option exercise | +11,148 | $7.51 | $83,721 |
| Aug 27, 2026 | Arcutis Biotherapeutics Inc. | Open-market sale | โ11,148 | $25.03 | $279,028 |
| Aug 27, 2026 | Arcutis Biotherapeutics Inc. | Option exercise | +27,052 | $8.63 | $233,459 |
| Aug 27, 2026 | Arcutis Biotherapeutics Inc. | Open-market sale | โ27,052 | $25.03 | $677,095 |
| Aug 20, 2026 | Arcutis Biotherapeutics Inc. | Option exercise | +1,072 | $7.51 | $8,051 |
| Aug 20, 2026 | Arcutis Biotherapeutics Inc. | Open-market sale | โ1,072 | $26.04 | $27,912 |
| Jun 5, 2026 | Arcutis Biotherapeutics Inc. | Grant or award | +5,778 | โ | โ |
| Jun 12, 2025 | Arcutis Biotherapeutics Inc. | Grant or award | +7,609 | โ | โ |
| Jan 21, 2025 | Phathom Pharmaceuticals Inc. | Open-market sale | โ19,109 | $6.59 | $125,928 |
| Nov 11, 2024 | Arcutis Biotherapeutics Inc. | Open-market sale | โ8,687 | $10.85 | $94,254 |
| Jul 15, 2024 | Phathom Pharmaceuticals Inc. | Open-market sale | โ33,848 | $11.72 | $396,699 |
| Jun 14, 2024 | Arcutis Biotherapeutics Inc. | Grant or award | +10,139 | โ | โ |
| Mar 22, 2024 | Phathom Pharmaceuticals Inc. | Open-market sale | โ16,851 | $9.11 | $153,513 |
| Nov 1, 2023 | Phathom Pharmaceuticals Inc. | Grant or award | +37,500 | โ | โ |
| Jul 14, 2023 | Phathom Pharmaceuticals Inc. | Grant or award | +200,000 | โ | โ |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.